Jolt Health Inc., Letter to the Shareholders
Jolt Health Inc., Letter to the Shareholders
- Continuing to build upon the Company's research initiative.
- Jolt is currently seeking several opportunities, adding to its health and wellness portfolio.
- Strategic focus to identify and target those companies that both have tangible quantifiable assets and strong commitment in the health and wellness, AI drug development and pharmaceutical sectors.
- 繼續在公司的研究計劃基礎上再接再厲。
- Jolt目前正在尋找多個機會,以增加其健康和保健產品組合。
- 戰略重點是識別和瞄準那些在健康和保健、人工智能藥物開發和製藥領域均擁有有形可量化資產和堅定承諾的公司。
VANCOUVER, BC / ACCESSWIRE / March 8, 2024 / Jolt Health Inc. ("JOLT" or "the Company") (CSE:JOLT), the Company is pleased to provide the following letter to shareholders, outlining the Company's advancements and an update on the direction of the Company.
不列顛哥倫比亞省溫哥華/ACCESSWIRE/2024年3月8日/Jolt Health Inc.(“JOLT” 或 “公司”)(CSE: JOLT),公司很高興向股東提供以下信函,概述公司的進展以及公司的最新發展方向。
To the Shareholders of Jolt Health Inc,
致Jolt Health Inc的股東,
We welcome this opportunity to provide our shareholders with a comprehensive outlook of Jolt's efforts in building upon its existing portfolio and establishing its future strategic imperatives by building upon Jolt's existing product portfolio, which is primarily focused on over the counter products.
我們很高興有機會向我們的股東全面介紹Jolt在現有產品組合基礎上所做的努力,並在Jolt現有產品組合的基礎上建立其未來的戰略要務,該產品組合主要側重於場外產品。
Jolt is exploring current opportunities in expanding its health and wellness portfolio by exploring opportunities in the AI drug development and pharmaceutical sectors. The Company is working to identify and assess biotechnology and pharmaceutical solutions to address a myriad of health concerns, a catalyst for growth in this bourgeoning market.
Jolt正在通過探索人工智能藥物開發和製藥領域的機會來探索當前擴大其健康和保健產品組合的機會。該公司正在努力確定和評估生物技術和製藥解決方案,以解決無數的健康問題,這是這個新興市場增長的催化劑。
The Company believes that it is at the beginning of a health and wellness renaissance and are looking to participate in the coming wave of interest. Focusing on business fundamentals of strong growth, service and operational excellence as the path to deliver meaningful results, including environmental and social impact is a key driver of how the Company plans to create shareholder value over the long term.
該公司認爲,它正處於健康和保健復興的開始,並希望參與即將到來的興趣浪潮。專注於強勁增長、服務和卓越運營等業務基本面,以此作爲實現包括環境和社會影響在內的有意義結果的途徑,是公司計劃長期創造股東價值的關鍵驅動力。
In addition, the Company would like to announce that Mr. Cody Corrubia has joined the board as a director. In accepting his resignation from the board, the Company wishes Mr. Mark Tommasi well in his future endeavours.
此外,公司想宣佈,科迪·科魯比亞先生已加入董事會擔任董事。在接受他辭去董事會職務時,公司祝願Mark Tommasi先生在未來的工作中一切順利。
We are also pleased to announce a private placement financing of up to 50,000,000 units of the Company (the "Units") at a price of $0.01 per Unit for aggregate gross proceeds of up to $500,000 (the "Offering").
我們還很高興地宣佈,以每單位0.01美元的價格爲公司高達5000萬個單位(“單位”)進行私募融資,總收益高達500,000美元(“本次發行”)。
Each Unit will be comprised of one common share in the capital of the Company (a "Common Share") and one half a warrant (a "Warrant"). Each whole warrant entitles the holder thereof to purchase one Common Share at a price of $0.05 per Common Share for a period of 2 years following the closing date of the Offering, subject to accelerated expiry as described herein. If, at any time, the closing price of the Company's Common Shares is greater than $0.15 per Common Share for 10 consecutive days, including days where there is no trading, the Company may provide written notice (a "Warrant Acceleration Notice") to the holders that the expiry of the Warrants shall be accelerated to a date that is not less than 30 days from the date of the Warrant Acceleration Notice.
每個單位將由公司資本中的一股普通股(“普通股”)和一半的認股權證(“認股權證”)組成。每份完整認股權證的持有人有權在自發行截止日起的2年內以每股普通股0.05美元的價格購買一股普通股,但如本文所述加速到期。如果公司普通股的收盤價在任何時候連續10天(包括沒有交易的日子)超過每股普通股0.15美元,則公司可以向持有人提供書面通知(“認股權證加速通知”),認股權證的到期時間應加快至自認股權證加速通知發佈之日起不少於30天的日期。
Thank you for your continued support. We are excited to have you along for the journey.
感謝您一直以來的支持。我們很高興你能一起踏上這段旅程。
On behalf of the Board of Directors,
我代表董事會,
Gerald Tritt
President and CEO
傑拉爾德·特里特
總裁兼首席執行官
About Jolt Health Inc.
關於 Jolt Health Inc.
With a focus on the global Health and Wellness markets, Jolt Health Inc. (CSE:JOLT) was founded in 2023, with a mission to bring to market innovative products that enhance health and wellness and provide an improved quality of life. Jolt Health holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.
Jolt Health Inc.(CSE: JOLT)專注於全球健康和保健市場,成立於2023年,其使命是向市場推出可增強健康和保健並改善生活質量的創新產品。Jolt Health擁有在歐洲、英國和北美生產、營銷、包裝、銷售和分銷受專利保護的治療和藥品的獨家許可。
For further information, please contact:
欲了解更多信息,請聯繫:
Investor Relations
Telephone: 1 (604) 343-2977
E-mail: investors@Jolt-Health.com
投資者關係
電話:1 (604) 343-2977
電子郵件:investors@Jolt-Health.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
加拿大證券交易所及其監管服務提供商(該術語在加拿大證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
Certain statements contained in this release may constitute "forward-looking statements" or "forward-looking information" (collectively "forward-looking information") as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated", "anticipates" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, financing, and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
本新聞稿中包含的某些陳述可能構成 “前瞻性陳述” 或 “前瞻性信息”(統稱爲 “前瞻性信息”),因爲這些術語在1995年《私人證券訴訟改革法》和類似的加拿大法律中使用。這些陳述與未來事件或未來表現有關。使用 “可能”、“打算”、“期望”、“相信”、“將”、“預測”、“估計”、“預期” 等任何詞語以及與非歷史事實相關的類似表述和陳述均旨在識別前瞻性信息,並基於公司目前對此類未來事件的結果和時間所持的看法或假設。未來的實際結果可能存在重大差異。特別是,本新聞稿包含與公司業務、融資和某些公司變更有關的前瞻性信息。本新聞稿中包含的前瞻性信息是截至本新聞稿發佈之日發佈的,除非適用的證券法要求,否則公司沒有義務更新或修改任何前瞻性信息,無論是由於新信息、未來事件還是其他原因。由於此處包含的風險、不確定性和假設,投資者不應過分依賴前瞻性信息。上述陳述明確限制了此處包含的任何前瞻性信息。
SOURCE: Jolt Health Inc.
資料來源:Jolt Health Inc.